Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...
Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...
Best bets for events, festivals, fairs and other things do in Nassau and Suffolk, from NYC to the East End on Long Island. Explore our interactive guide to weekend fun, including family-friendly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results